Arlene S. Chan

Arlene S. Chan

Mount Hospital
Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Journal: Breast cancer research and treatment

Published: February 18, 2026

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Journal: Future oncology (London, England)

Published: December 29, 2025

Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset.

Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset.

Journal: The oncologist

Published: September 01, 2025

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 27, 2025

Short-term moderate-intensity treadmill running may confer a greater benefit to bone strength than high-intensity treadmill running in 12-month-old C57BL/6 mice.

Short-term moderate-intensity treadmill running may confer a greater benefit to bone strength than high-intensity treadmill running in 12-month-old C57BL/6 mice.

Journal: Bone

Published: May 29, 2025

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Journal: The oncologist

Published: May 07, 2025

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 12, 2025

Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer.

Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer.

Journal: JCO precision oncology

Published: December 06, 2024

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.

Journal: International journal of cancer

Published: September 18, 2024

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 21, 2024

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).

Journal: Breast cancer research : BCR

Published: May 15, 2024

Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Journal: Breast cancer research and treatment

Published: March 05, 2024

Showing 1-12 of 87

Last Updated: 09/26/2026